Citations

Clear

477 citation(s) found for "Wallace, AM".

Correction: Learning curve and competence for volumetric laser endomicroscopy in Barrett’s esophagus using cumulative sum analysis
Inamdar, Sumant , Smith, Michael S. , Rosen, Lisa, Han, Dennis , Chang, Kenneth J. , Leggett, Cadman, Lightdale, Charles J. , Sejpal, Divyesh V., Tearney, Guillermo J. , Thomas, Rebecca, Wallace, Michael B. , Leggett, Cadman L. , Wallace, Michael B , Leggett, Cadman L , Trindade, Arvind J. , Pleskow, Douglas K.

Mayo Clinic

Endoscopy | July 27, 2018 | Volume: 50 | Issue: 05 | Pages: C10-C10

10.1055/a-0658-2867 | PMID 30053760 Get It

THE IMPACT OF WEEKEND ADMISSION ON ACUTE CHOLANGITIS OUTCOMES: A NATIONWIDE ANALYSIS OF 67,630 PATIENTS
Kröner, PT, García, A Martínez-Alcalá, D'Assunção, MA, Wallace, Mary Anderson, Mönkemüller, Klaus, García, A Martínez-Alcalá

Mayo Clinic

Endoscopy | July 10, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1637187 Get It

Smoking and Risk of Non-Hodgkin Lymphoma Subtypes in a Cohort of Older Women
Parker, Alex S., Dick, Fred R., Kemp, John D., Wallace, Robert B. , Sellers, Thomas A. , Folsom, Aaron R. , Cerhan, James R. , Habermann, Thomas M.

Mayo Clinic

Leukemia & Lymphoma | July 2, 2018 | Volume: 37 | Issue: 3-4 | Pages: 341-349

10.3109/10428190009089434 | PMID 10752985 Get It

Volumetric laser endomicroscopy in the biliary and pancreatic ducts: a feasibility study with histological correlation
Mousa, Omar Y. , Krishna, Murli , Pursell, Khela R., Afsh, Mohammad, Harnois, Denise M. , Wolfsen, Herbert C. , Wallace, Michael B. , Lukens, Frank , Corral, Juan E. , Lukens, Frank J., Wallace, Michael B , Levink, Iris J. M. , Kröner, Paul T.

Mayo Clinic

Endoscopy | June 18, 2018 | Volume: 50 | Issue: 11 | Pages: 1089-1094

10.1055/a-0631-1634 | PMID 29913531 Get It

Abstract Background Volumetric laser endomicroscopy (VLE) provides circumferential images 3 mm into the biliary and pancreatic ducts. We aimed to correlate VLE images with the normal and abnormal microstructure of these ducts. Methods: Samples from patients undergoing hepatic or pancreatic resection were evaluated. VLE images were collected using a low-profile VLE catheter inserted manually into the biliary and pancreatic ducts ex vivo. Histological correlation was assessed by two unblinded investigators. Results 25 patients (20 liver and 5 pancreatic samples) and 111 images were analyzed. VLE revealed three histological layers: epithelium, connective tissue, and parenchyma. It identified distinctive patterns for primary sclerosing cholangitis (PSC), pancreatic cysts, neuroendocrine tumor, and adenocarcinoma adjacent to the pancreatic duct or ampulla. VLE failed to identify dysplasia in a dominant stricture and inflammatory infiltrates in PSC. Reflectivity measurements of the liver parenchyma diagnosed liver cirrhosis with high sensitivity. Conclusions VLE can identify histological changes in the biliary and pancreatic ducts allowing real-time diagnosis. Further studies are needed to measure the accuracy of VLE in a larger sample and to validate our findings in vivo.
Bronchiolar Adenoma
Borsu, Laetitia , Lu, Shaohua, Larsen, Brandon T. , Sae‐Ow, Wichit, Mackinnon, Alexander C. , Bowman, Anita S. , Arcila, Maria E. , Ladanyi, Marc , Chang, Jason C. , Montecalvo, Joseph , Wallace, William D. , Kim, Hyunjae Ryan , Sauter, Jennifer L. , Travis, William D. , Rekhtman, Natasha

Mayo Clinic

American Journal of Surgical Pathology | May 24, 2018 | Volume: 42 | Issue: 8 | Pages: 1010-1026

10.1097/pas.0000000000001086 | PMID 29846186 Get It

We have identified 25 lesions involving alveolar lung parenchyma characterized by nodular proliferation of bland bilayered bronchiolar-type epithelium containing a continuous layer of basal cells. These lesions shared some histologic features with the recently described entity of ciliated muconodular papillary tumor (CMPT); however, the majority did not fit all diagnostic criteria in that they exhibited only focal or absent papillary architecture, and they had variable number of ciliated and mucinous cells, with some lesions entirely lacking 1 or both of these components. The morphologic and immunohistochemical features ranged from those resembling proximal bronchioles (proximal-type: moderate to abundant mucinous and ciliated cells; negative or weak TTF1 in luminal cells; n=8) to those resembling respiratory bronchioles (distal-type: scant or absent mucinous and ciliated cells; positive TTF1 in luminal cells; n=17). The hallmark of all lesions was a continuous layer of basal cells (p40 and CK5/6-positive). We provisionally designated these lesions as bronchiolar adenomas (BAs) and analyzed their clinicopathologic and molecular features. All BAs were discrete, sharply circumscribed lesions with a median size of 0.5 cm (range, 0.2 to 2.0 cm). Most lesions were either entirely flat (n=14) or contained focal papillary architecture (n=7); only 4 lesions, all proximal-type, were predominantly papillary, fitting the classic description of CMPT. Notably, of 9 lesions submitted for frozen section evaluation, 7 were diagnosed as adenocarcinoma. No postsurgical recurrences were observed for any lesions (median follow-up, 11 mo). Twenty-one BAs underwent next-generation sequencing and/or immunohistochemistry for BRAF V600E, revealing mutation profiles similar to those previously described for CMPTs, including BRAF V600E mutations (n=8, 38%), unusual EGFR exon 19 deletions (n=2, 10%), EGFR exon 20 insertions (n=2, 10%), KRAS mutations (n=5, 24%), and HRAS mutations (n=1, 5%). The mutation profiles were similar in proximal-type and distal-type lesions. In conclusion, we describe a family of putatively benign clonal proliferations with a spectrum of morphology recapitulating various levels of the bronchiolar tree, of which only a minor subset fits the classic description of CMPT. Comparable mutation profiles and partially overlapping morphologic features across the spectrum of these lesions support their nosological relationship. We propose designating this entire family of lesions as BAs, and that lesions currently designated CMPTs represent a subgroup of this family.
Outcome of long benign esophageal strictures undergoing endoscopictherapy: a tertiary center experience
Pang, Maoyin , Brand, Eelco C. , Brahmbhatt, Bhaumik , Patel, Krupa , Simons-Linares, C. Roberto , Wolfsen, Herbert C. , Wallace, Michael B. , Woodward, Timothy A., Wallace, Michael B , Bartel, Michael J. , Raimondo, Massimo

Mayo Clinic

Diseases of the Esophagus | May 1, 2018 | Volume: 31 | Issue: 10 | Pages: No page available

10.1093/dote/doy040 | PMID 29718161 Get It

Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Chiang, Angie C.A. , Fowler, Stephanie , Savjani, Ricky R. , Hilsenbeck, Susan G. , Wallace, Clare E. , Cirrito, John R. , Das, Pritam , Jankowsky, Joanna L. , Savjani, Ricky R. , Hilsenbeck, Susan Galloway

Mayo Clinic

Journal of Experimental Medicine | April 6, 2018 | Volume: 215 | Issue: 5 | Pages: 1349-1364

10.1084/jem.20171484 | PMID 29626114 Get It

Drug development for Alzheimer’s disease has endeavored to lower amyloid β (Aβ) by either blocking production or promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to improve pathological measures of disease over single treatment; however, the impact on cellular and cognitive functions affected by Aβ has not been tested. We used a controllable APP transgenic mouse model to test whether combining genetic suppression of Aβ production with passive anti-Aβ immunization improved functional outcomes over either treatment alone. Compared with behavior before treatment, arresting further Aβ production (but not passive immunization) was sufficient to stop further decline in spatial learning, working memory, and associative memory, whereas combination treatment reversed each of these impairments. Cognitive improvement coincided with resolution of neuritic dystrophy, restoration of synaptic density surrounding deposits, and reduction of hyperactive mammalian target of rapamycin signaling. Computational modeling corroborated by in vivo microdialysis pointed to the reduction of soluble/exchangeable Aβ as the primary driver of cognitive recovery.
Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report
Pottier, Cyril , Rampersaud, Evadnie , Baker, Matt , Wu, Gang , Wuu, Joanne , McCauley, Jacob L. , Schüle, Rebecca , Bermudez, Christin, Cooley, Anne , Wallace, Marielle, Zhang, Jinghui , Benatar, Michael , Rademakers, Rosa , Pottier, Cyril , Wuu, Joanne , Züchner, Stephan , Hussain, Sumaira , Taylor, J. Paul , Wu, Gang , McCauley, Jacob L

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | March 21, 2018 | Volume: 19 | Issue: 5-6 | Pages: 469-471

10.1080/21678421.2018.1452947 | PMID 29558868 Get It

Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer
Kandel, Pujan , Wallace, Michael B. , Wallace, Michael B

Mayo Clinic

Cancers | February 20, 2018 | Volume: 10 | Issue: 2 | Pages: 54

10.3390/cancers10020054 | PMID 29463004 Get It

Pancreas cancer is a lethal cancer as the majority patients are diagnosed at an advanced incurable stage. Despite improvements in diagnostic modalities and management strategies, including surgery and chemotherapies, the outcome of pancreas cancer remains poor. Endoscopic ultrasound (EUS) is an important imaging tool for pancreas cancer. For decades, resected pancreas cancer and other cancer specimens have been used to identify tissue biomarkers or genomics for precision therapy; however, only 20% of patients undergo surgery, and thus, this framework is not useful for unresectable pancreas cancer. With advancements in needle technologies, tumor specimens can be obtained at the time of tissue diagnosis. Tumor tissue can be used for development of personalized cancer treatment, such as performing whole exome sequencing and global genomic profiling of pancreas cancer, development of tissue biomarkers, and targeted mutational assays for precise chemotherapy treatment. In this review, we discuss the recent advances in tissue acquisition of pancreas cancer.
An International Multispecialty Validation Study of the IgG4‐Related Disease Responder Index
Wallace, Zachary S. , Khosroshahi, Arezou , Carruthers, Mollie D., Perugino, Cory A. , Campochiaro, Corrado , Culver, Emma , Cortazar, Frank B. , Ebbo, Mikaël , Fernandes, Ana D. , Frulloni, Luca , Hart, Phil A. , Karadağ, Ömer , Kawa, Shigeyuki , Kim, Myung‐Hwan , Lanzillotta, Marco , Matsui, Shoko , Okazaki, Kazuichi , Ryu, Jay H. , Saeki, Takako , Schleinitz, N. , Tanasa, Paula, Umehara, Hisanori , Webster, George, Stone, John H. , Ryu, Jay H , Carruthers, Mollie D., Choi, Hyon K. , Della‐Torre, Emanuel , Kawano, Mitsuhiro , Zhang, Wen , Campochiaro, Corrado

Mayo Clinic

Arthritis Care & Research | February 18, 2018 | Volume: 70 | Issue: 11 | Pages: 1671-1678

10.1002/acr.23543 | PMID 29457382 Get It

ObjectiveIgG4‐related disease (IgG4‐RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4‐RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation.MethodsThe RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4‐RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness.ResultsThe 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P < 0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P < 0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively.DiscussionIn this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy.